Josep M. Llovet, MD, PhD is Director of the Liver Cancer Program and Professor of Medicine (Division of Liver Diseases) at the Icahn School of Medicine at Mount Sinai. He is also Professor of Medicine-Hepatic Oncology at the University of Barcelona and Professor of Research-ICREA in the Liver Unit at IDIBAPS-Hospital Clínic of Barcelona.

Dr. Llovet was the Founder and has been President of the International Liver Cancer Association. He has chaired and contributed to the development of more than 10 guidelines related to clinical management and clinical trial design in liver cancer. He was Chairman of the European Association for the Study of Liver Disease (EASL)-Clinical Practice Guidelines 2012, President of the American Association for the Study of Liver Diseases Special Interest Group in Hepatobiliary Neoplasia, and a member of the Educational Committee of EASL. He has published more than 345 articles in peer-reviewed journals (with more than 145,000 citations) and more than 55 book chapters, and has delivered more than 675 lectures. He is Editor in Chief of JHEP Reports and has been Associate/Senior Editor of Journal of Hepatology and Clinical Cancer Research. Dr. Llovet has been a Top-1% cited researcher in Clarivate Analytics since 2014.

Dr. Llovet has devoted his career to studying the pathogenesis and treatment of liver cancer. He received the American Association for Cancer Research-Landon International Award (2009) and the International Hans Popper Award (2012), and has received competitive funding from the National Cancer Institute, European Commission, and other grantors for more than 100 research projects.

Professor Llovet obtained his degree in Medicine and Surgery from the University of Barcelona in 1986 and his PhD from the Autonomous University of Barcelona in 1995. He has been working in clinical and translational research in hepatocellular carcinoma (HCC) and cholangiocarcinoma (ICC) for the last 25 years. He is leading international randomized trials in HCC on novel targeted therapies and developing a molecular classification of the disease, understanding the genetic aberrations and signaling pathways involved and in the identification of new molecular targeted therapies. He has organized the HCC Genomic Consortium and the HEPTROMIC Consortium that includes several international HCC research centers: IDIBAPS-Hospital Clínic, Icahn School of Medicine at Mount Sinai, INSERM, Univ. Tuebingen, Dana-Farber-MIT-Broad Institute and NCI. He has received the AACR-Landon International Award (2009) for leading the International HCC Genomic Consortium, the International Hans Popper award (2012), Premi Josep Trueta (2013) and was nominated as Fellow of the American Association for the Study of Liver Diseases (FAASLD-2015). Top 1% most cited researcher globally by Clarivate Analytics (2014-20).